Assessment of Lipid Dysfunction of Patients Under Haemodialysis in Cameroon
American Journal of Biomedical and Life Sciences
Volume 5, Issue 4, August 2017, Pages: 63-68
Received: Apr. 18, 2017; Accepted: May 6, 2017; Published: Jul. 6, 2017
Views 1659      Downloads 169
Authors
Cédric Gueguim, Départment of Biochemistry, University of Yaoundé I, Central Region, Cameroon
Lucien Etamé Soné, Départment of Biochemistry, University of Yaoundé I, Central Region, Cameroon; Institute of Medical Research and Medicinal Plants (IMPM), Central Region, Cameroon
Henriette Thérèse Dimodi, Départment of Biochemistry, University of Yaoundé I, Central Region, Cameroon; Institute of Medical Research and Medicinal Plants (IMPM), Central Region, Cameroon
Marie Patrice Halle, Faculty of Medicine and Pharmaceutical Sciences, University of Douala, Littoral Region, Cameroon
François Kaze Folefack, Faculty of Medicine and Biomédical Sciences, University of Yaoundé I, Central Region, Cameroon
Constant Anatole Pieme, Faculty of Medicine and Biomédical Sciences, University of Yaoundé I, Central Region, Cameroon
Nnanga Nga, Institute of Medical Research and Medicinal Plants (IMPM), Central Region, Cameroon; Faculty of Medicine and Pharmaceutical Sciences, University of Douala, Littoral Region, Cameroon; Faculty of Medicine and Biomédical Sciences, University of Yaoundé I, Central Region, Cameroon
Wilfred Mbacham, Départment of Biochemistry, University of Yaoundé I, Central Region, Cameroon; Faculty of Medicine and Biomédical Sciences, University of Yaoundé I, Central Region, Cameroon
Article Tools
Follow on us
Abstract
Dyslipidaemia is a major risk factor of cardiovascular disease of patients under haemodialysis. Both increase and decrease of cholesterol levels are associated with higher cardiovascular mortality rate in haemodialysis patients. The objective of this study was to assess the lipid dysfunction among patients maintained under haemodialysis in two reference centres of haemodialysis in Cameroon. A descriptive comparative study was carried out in Nephrology Unit of the University Teaching Hospital of Yaoundé and the same Unit of the Douala General Hospital, Cameroon. A total of 160 subjects were studied: Of these, there were 80 patients under haemodialysis and 80 healthy controls. Body mass index (BMI) was measured according to WHO’s guidelines. Serum total cholesterol (TC), triglycerides (TG) and high-density lipoprotein cholesterol (HDL-C) were assayed before and after haemodialysis session. Low-density lipoprotein cholesterol (LDL-C) was calculated using Friedwald’s equation. Their cardiovascular risk indices (TC / HDL-C) were also determined. Patients under haemodialysis had significantly lower BMI as compared with the healthy controls (p < 0.05). Total Cholesterol, LDL-C and HDL-C were considerably lower before and after haemodialysis compared with the healthy controls (p ˂ 0.05). A non-significant difference was found between Triglycerides before and after haemodialysis in contrast with the healthy controls (p > 0.05). The cardiovascular risk indices (TC / HDL-C) of the patients under haemodialysis were higher than those of the healthy control group. Patients under haemodialysis had quite low BMI, total Cholesterol, LDL-C and HDL-C depicting malnutrition leading to inflammation, accelerated atherosclerosis process and cardiovascular complications.
Keywords
Total Cholesterol, Lipoproteins, BMI, Haemodialysis, Cardiovascular Disease
To cite this article
Cédric Gueguim, Lucien Etamé Soné, Henriette Thérèse Dimodi, Marie Patrice Halle, François Kaze Folefack, Constant Anatole Pieme, Nnanga Nga, Wilfred Mbacham, Assessment of Lipid Dysfunction of Patients Under Haemodialysis in Cameroon, American Journal of Biomedical and Life Sciences. Vol. 5, No. 4, 2017, pp. 63-68. doi: 10.11648/j.ajbls.20170504.11
Copyright
Copyright © 2017 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
[1]
Pennell P, Leclercq B, Delahunty M, Walters B. (2006). The utility of non-HDL in managing dyslipidemia of stage 5 chronic kidney diseases. Clinic Nephrolog., 66 (5), 336-47.
[2]
Abrass C. (2006). Lipid metabolism and renal disease. Contrib Nephrology. 151: 106-21.
[3]
National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease (2002). Evaluation, classification, and stratification. American Journal of Kidney Disease. 39: S1-266.
[4]
Gowdak L, Arantes R, Krieger E. (2007). Under use of American College of Cardiology/American Heart Association Guidelines in haemodialysis patients. Ren Fail. 29 (5), 559-65.
[5]
Soubassi L, Papadakis E, Theodoropoulos I, Poulos G, Chaniotis D, Tsapakidis I., et al. (2007). Incidence and risk factors of coronary artery disease in patients on chronic hemodialysis., International Artif Organs. 30 (3), 253-7.
[6]
Wakeel S, Mitwalli A, Mohaya S, Abu-Aisha H, Tarif N, Malik G., et al (2002). Morbidity and mortality in ESRD patients on dialysis. Saudi Journal of Kidney Disease Transplantation. October-December; 13 (4): 473-7.
[7]
Muntner P, He J, Astor B, Folsom A, Coresh J. (2005). Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the atherosclerosis risk in communities study. American Journal of Nephrology. 16 (2): 529-38.
[8]
Iseki K, Yamazato M, Tozawa M, Takishita S. (2002). Hypocholesterolemia is a significant predictor of death in a cohort of chronic hemodialysis patients. Kidney International Journal. 61: 1887-93.
[9]
Liu Y, Coresh J, Eustace J, Longenecker J, Jaar B, Fink N., et al.(2004). Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. JAMA, 291: 451-9.
[10]
Kalantar-Zadeh K, Block G, Humphreys M, Kopple J. (2003). Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney International Journal, 63 (3): 793-808.
[11]
Allain C, Poon L, Richmond, W and Fu. (1974). Enzymatic determination of serum cholesterol. P. D. Clin. Chem, 20: 470.
[12]
Fossati R, Prencipe L. (1982). Serum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide. Clin Chem, 28: 2077.
[13]
Friedwald W, Levy R, Fredrickson D. (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of preparative ultracentrifuge. Clin Chem, 18: 499-502.
[14]
Bednarek-Skublewska A, Baranowicz-Gaszczyk I, Jóźwiak L, Dzik M, Majdan M, Ksiazek A. (2005). Comparison of some nutritional parameters in hemodialysis patients over and below 65 years of age. Pol Arch Med Wewn. 113 (5): 417-23.
[15]
Basaleem H, Alwan S, Ahmed A, Al-Sakkaf K.(2004). Assessment of the nutritional status of end-stage renal disease patients on maintenance hemodialysis. Saudi Journal Kidney Disease Transplantation. October-ecember; 15 (4): 455-6.
[16]
Torun D, Micozkadioglu H, Torun N, Ozelsancak R, Sezer S, Adam F., et al.(2007). Increased body mass index is not a reliable marker of good nutrition in hemodialysis patients. Ren Fail. 29 (4): 487-93.
[17]
Physical status: the use and interpretation of anthropometry. (1995). Report of a WHO Expert Committee. Geneva, World health Organization, WHO Technical Report Series, No. 854.
[18]
Johansen K, Young B, Kaysen G, Chertow G. (2004). Association of body size with outcomes among patients beginning dialysis. American Journal of Clinical Nutrition. 80: 324-32.
[19]
Leavey S, McCullough K, Hecking E, Goodkin D, Port F, Young E. (2001). Body mass index and mortality in 'healthier' as compared with 'sicker' haemodialysis patients: Results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant. 16: 2386-94.
[20]
Kalantar-Zadeh K, Kilpatrick R, Kopple J, Stringer W. (2005). A matched comparison of serum lipids between hemodialysis patients and nondialysis morbid controls. Hemodialysis International Journal. Jul; 9 (3): 314-24.
[21]
Ashfaq A, Abdul H, Dilshad A, Muhammad K, Fatima T, Imran S. (2007): Assessment of lipid dysfunction in patients on maintenance haemodialysis; J Ayub Med Coll Abbottabad 19 (4): 32-36.
[22]
Longenecker J, Coresh J; Powe N; Levey A; Fink N; Martin A., et al. (2002). Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: the CHOICE Study. American Journal of Nephrology. 13 (7): 1918-27.
[23]
Caparevic Z, Kostic N.(2007). The influence of age and the beginning of menopause on the lipid status, LDL oxidation, and CRP in healthy women. Srp Arh Celok Lek. 2007 May-Jun; 135 (5-6): 280-5.
[24]
Trémollieres F, Pouilles J, Cauneille C, Ribot C. (1999). Coronary heart disease risk factors and menopause: a study in 1684 French women. Atherosclerosis. 142 (2): 415-23.
[25]
Jang C, Bell R, White V, Lee P, Dwyer K, Kerr P., et al. (2001). Women's health issues in haemodialysis patients. Med J Aust. 175 (6): 298-301.
[26]
Shamim A, Ihteshamul H. (2004). Association of ABO, Rh blood groups systems with lipids and other anthropometric co variables as predictors of cardiovascular risk in NWFP, Pakistan. Ann King Edward Med Coll. 10 (2): 166-9.
[27]
Kilpatrick R, McAllister C, Kovesdy C, Derose S, Kopple J, Kalantar-Zadeh K. (2007) Association between serum lipids and survival in hemodialysis patients and impact of race. American Journal of Nephrology. 18 (1): 293-303.
[28]
Kalantar-Zadeh K. (2005). Recent advances in understanding the malnutrition-inflammation-cachexia syndrome in chronic kidney disease patients: What is next? Semin Dialysis. Sep-Oct; 18 (5): 365-9.
[29]
Kalantar-Zadeh K, Ikizler T, Block G, Avram M, Kopple J (2003). Malnutrition-inflammation complex syndrome in dialysis patients: causes and consequences. American Journal of Nephrology. 42 (5): 864-81.
[30]
Kharrat I, Jmal A, Jmal L, Amira Z, Cheikh W, Bourouba B et al (2012). Altération du métabolisme lipidique chez les hémodialysés. La Tunisie Medicale. 90 (07): 537-541.
[31]
Deicher R, Ziai F, Bieglmayer C, Schillinger M, Horl W. (2005). Low total vitamin C plasma level is a risk factor for cardiovascular morbidity and mortality in hemodialysis patients. American Journal of Nephrology. 16 (6): 1811-8.
[32]
Rauchhaus M, Coats A, Anker S. (2000) The endotoxin-lipoprotein hypothesis. Lancet. 356 (9233): 930-3.
[33]
Horl W, Cohen J, Harrington J, Madias N, Zusman C. (2004). Atherosclerosis and uremic retention solutes. Kidney International Journal 66 (4): 1719-31.
[34]
Bro S, Bentzon J, Falk E, Andersen C, Olgaard K, Nielsen L (2003). Chronic renal failure accelerates atherogenesis in apolipoprotein E-deficient mice. American Journal of Nephrology. 14 (10): 2466-74.
[35]
Pawlaczyk K, Oko A, Lindholm B. (2003). Czekalski S. Malnutrition-inflammation-atherosclerosis (MIA syndrome) in patients with renal failure. Pol Merkur Lekarski. 15 (88): 334-43.
[36]
Painter P. (2005). Physical functioning in end-stage renal disease patients. Hemodialysis International Journal. 9 (3): 218-35.
[37]
Iffat A, Riffat K, Imran A, Munir A. (2000). The Effect of Physical fitness on Plasma Lipids in Young Pakistani Male Medical Students. J Rawal Med Coll Dec 2000; 4 (1-2): 34-8.
[38]
Kouidi E, Grekas D, Deligiannis A, Tourkantonis A. (2004). Outcomes of long-term exercise training in dialysis patients: comparison of two training programs. Clinical Nephrologie. 61: S31-8.
ADDRESS
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
U.S.A.
Tel: (001)347-983-5186